[FDA breakthrough device designation] Shield ™ MCD

Guardant Health’s multi-cancer detection (MCD) test* is a blood-based test designed to detect 10 types of cancer, including bladder cancer, breast cancer, colorectal cancer, esophageal cancer, stomach cancer, liver cancer (hepatocellular carcinoma), lung cancer, pancreatic cancer, prostate cancer, and ovarian cancer.

For individuals without symptoms, cancer screening can help detect cancer at an early stage. By the time symptoms appear, cancer is often already at a more advanced stage [1]. Early detection of cancer signs can improve survival rates and reduce mortality [1–3]. Overall, MCD testing has the potential to increase screening rates through a single blood test, thereby enhancing cancer detection capabilities [2].

Guardant Health’s multi-cancer detection (MCD) test* is not suitable for pregnant women or individuals who have previously been diagnosed with cancer. Your clinical eligibility will be determined by the medical professional with whom you have scheduled an appointment. There are no other restrictions for undergoing this test.

Guardant Health’s MCD test* is intended to complement routine cancer screening and does not replace standard, age-recommended cancer screening tests.

References:
[1] Madar, S.; Amor, R.E.; Furman-Assaf, S.; Friedman, E. Innovative Approaches to Early Detection of Cancer-Transforming Screening for Breast, Lung, and Hard-toScreen Cancers. Cancers 2025, 17, 1867. https://doi.org/10.3390/cancers17111867   
[2] Carbonell C, Hutchinson JM, Hilsden RJ, Yang H, Brenner DR. Blood-Based MultiCancer Early Detection Tests (MCEDs) as a Potential Approach to Address Current Gaps in Cancer Screening. Cancer Control. 2024 Jan-Dec;31:10732748241307360. doi: 10.1177/10732748241307360   
[3] Montena, J. (2024). Early cancer diagnosis: A crucial step toward better outcomes. Journal of Cancer Diagnosis, 2024(1), 1–5.   

 

• Estimated report turnaround time: 2-3 weeks upon sample arrived at Guardant Health's Laboratory
• Once your test report is ready, you will be notified by the clinic to make an appointment for collection and explanation.
• This test report is currently available in English only.

1. You can place an order on our E-Shop here.
2. After the order is confirmed, we will contact you by phone within two business days to help arrange an appointment. You may also call +852 3008 2562 or make an appointment via WhatsApp/WeChat at +852 9504 7481.
3. During the call/WhatsApp, we will: (a). Collect basic personal information (e.g. name and date of birth)
   (b). Provide the address of the designated clinic
   (c). Offer available appointment time slots for your selection
   
4. To ensure sample quality and transportation arrangements to the United States, medical consultation and blood collection can only be scheduled Monday to Friday. Appointments are not available on Saturdays, Sundays, or public holidays.
5. Once the appointment is confirmed, you will receive a confirmation message and important notes via WhatsApp or WeChat. We will also reconfirm that your personal information is correct.
6. On the day of your blood draw: (a). Bring your original identification document to the clinic for registration
   (b). Staff will arrange your medical consultation and blood collection (approximately 30–45 minutes)
   (c). No fasting or special preparation is required
   (d). The date for explaining your test report will be scheduled on the same day
   
7. After the blood draw, our staff will collect and transport your sample to the laboratory. You do not need to, and should not, take the sample out of the clinic yourself.
8. The test report will be completed approximately 2–3 weeks after the sample arrives at the Guardant Health laboratory in the United States. It will then be sent to the clinic where you had your consultation.
9. You may visit the clinic at your scheduled date and time, where the doctor will explain the report to you.

Guardant Health Launches Shield Multi-Cancer Detection (MCD) Test in Multiple Markets in Asia with Manulife Partnership | Guardant Health Investor Relations